EPCAM and colorectal carcinoma: Specifically, MOC31PE, composed of EpCAM antibody and the complete Pseudomonas exotoxin A (PE), has shown significant survival extension in patients with metastatic CRC when used as a monotherapy, and has also been shown to provoke antitumor immunity through the induction of ICD However, the potential of toxin delivery with CDH17 targeting in CRC remains to be investigated.